Summary
This filing represents an amendment to Amgen Inc.'s (AMGN) Quarterly Report on Form 10-Q for the period ending June 30, 2015. The primary purpose of this amendment is to provide a corrected Exhibit 10.18, an agreement between Amgen Inc. and Jonathan Graham dated May 11, 2015. No other financial information or disclosures within the original Form 10-Q are altered by this amendment. Investors should note that this filing does not introduce new financial performance data or operational updates for the second quarter of 2015. The original Form 10-Q, filed on August 5, 2015, would contain the substantive financial and operational details. This amendment focuses solely on the correction of a specific exhibit, ensuring the completeness and accuracy of the SEC filing record.
Financial Highlights
55 data points| Revenue | $5.37B |
| Cost of Revenue | $1.09B |
| Gross Profit | $4.14B |
| SG&A Expenses | $1.16B |
| Operating Expenses | $3.29B |
| Operating Income | $2.08B |
| Interest Expense | $277.00M |
| Net Income | $1.65B |
| EPS (Basic) | $2.18 |
| EPS (Diluted) | $2.15 |
| Shares Outstanding (Basic) | 760.00M |
| Shares Outstanding (Diluted) | 768.00M |
Key Highlights
- 1This is an amendment (10-Q/A) to the original Form 10-Q filed on August 5, 2015, for the quarter ended June 30, 2015.
- 2The amendment's sole purpose is to correct Exhibit 10.18, an agreement between Amgen Inc. and Jonathan Graham dated May 11, 2015.
- 3No other information or financial disclosures within the original Form 10-Q are amended.
- 4This filing does not contain new financial performance data or operational updates for the quarter.
- 5The company has provided updated certifications from its CEO and CFO as required by Rule 13a-14(a) in connection with this amendment.
- 6Amgen Inc. is identified as a large accelerated filer.
- 7The filing does not include Section 1350 certifications as no financial statements are being refiled.